Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
   
Ask the Experts About

Choosing Your MedsChoosing Your Meds
          
Rollover images to visit our other forums!
Recent AnswersAsk a Question
  
  • Email Email
  • Glossary Glossary


Lipoatrophy
Jun 3, 2006

I've just started on on a regimen of lamivudine, zidovudine and strocin.

I just would like to know if lipoatrophy affects everyone on HIV treatment. If not, then what is the percentage of people with lipoatrophy? Has studies been made?

Thanks!

Response from Dr. Young

Thanks for your post.

Lipodystrophy is a common, but certainly not universal complication. Lipo is clearly more common among persons who start treatment with lower CD4 counts or who have been infected for a very long time; it's also much more common among persons who are taking a d4T (Zerit)-containing regimen.

The frequency of lipo depends a lot on the group of patients studied and their demographical characteristics. In most recent studies (like the the recent Gilead 934 study- comparing your regimen to tenofovir/FTC/efavirenz), the rate of lipo after 2 years was very, very low.

I hope this helps, BY



Previous
Just Positive
Next
drug combo for salvage after Combivir

  
  • Email Email
  • Glossary Glossary

 Get Email Notifications When This Forum Updates or Subscribe With RSS


 
Advertisement



Q&A TERMS OF USE

This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.

Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.

Review our complete terms of use and copyright notice.

Powered by ExpertViewpoint

Advertisement